PubMed

HER2 therapy: molecular mechanisms of trastuzumab resistance.

Nahta R, Esteva FJ.

Breast Cancer Res. 2006;8(6):215. Review.PMID: 17096862 [PubMed - indexed for MEDLINE]Related articlesFree article

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.

Nat Clin Pract Oncol. 2006 May;3(5):269-80. Review.PMID: 16683005 [PubMed - indexed for MEDLINE]Related articles

Mechanisms of trastuzumab resistance in breast cancer.

Tolaney SM, Krop IE.

Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. Review.PMID: 19275526 [PubMed - indexed for MEDLINE]Related articles

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C.

Cancer Res. 2008 Mar 1;68(5):1471-7.PMID: 18316611 [PubMed - indexed for MEDLINE]Related articlesFree article

Trastuzumab: mechanisms of resistance and therapeutic opportunities.

Calabrich A, Fernandes Gdos S, Katz A.

Oncology (Williston Park). 2008 Oct;22(11):1250-8; discussion 1259, 1263. Review.PMID: 18980023 [PubMed - indexed for MEDLINE]Related articles

Treatment of HER2-positive metastatic breast cancer following initial progression.

Mayer IA.

Clin Breast Cancer. 2009 Jun;9 Suppl 2:S50-7. Review.PMID: 19596643 [PubMed - indexed for MEDLINE]Related articles

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.

Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C.

Breast Cancer Res Treat. 2009 Nov;118(1):113-24. Epub 2009 May 5.PMID: 19415485 [PubMed - indexed for MEDLINE]Related articles

Resistance to trastuzumab: a necessary evil or a temporary challenge?

Cardoso F, Piccart MJ, Durbecq V, Di Leo A.

Clin Breast Cancer. 2002 Oct;3(4):247-57; discussion 258-9. Review.PMID: 12425752 [PubMed - indexed for MEDLINE]Related articlesFree article

Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.

Conte P, Guarneri V, Bengala C.

Clin Breast Cancer. 2007 Dec;7(11):841-9. Review.PMID: 18269773 [PubMed - indexed for MEDLINE]Related articles

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. Epub 2009 Nov 2. Review.PMID: 19884552 [PubMed - indexed for MEDLINE]Related articles

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.PMID: 16887935 [PubMed - indexed for MEDLINE]Related articlesFree article

Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.

Rowe DL, Ozbay T, Bender LM, Nahta R.

Mol Cancer Ther. 2008 Jul;7(7):1900-8.PMID: 18645000 [PubMed - indexed for MEDLINE]Related articlesFree article

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.

Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, Lesko SM, Brogi E, Jones FE.

Mol Cancer Ther. 2009 Aug;8(8):2152-62. Epub 2009 Aug 11.PMID: 19671734 [PubMed - indexed for MEDLINE]Related articles

Her2 cross talk and therapeutic resistance in breast cancer.

Bender LM, Nahta R.

Front Biosci. 2008 May 1;13:3906-12. Review.PMID: 18508484 [PubMed - indexed for MEDLINE]Related articlesFree article

Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.

Menendez JA, Vellon L, Lupu R.

Med Hypotheses. 2005;64(5):997-1001.PMID: 15780499 [PubMed - indexed for MEDLINE]Related articles

Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.

Spector N.

Clin Breast Cancer. 2008 Mar;8 Suppl 3:S94-9. Review.PMID: 18777948 [PubMed - indexed for MEDLINE]Related articles

Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.

Emens LA.

Am J Ther. 2005 May-Jun;12(3):243-53. Review.PMID: 15891269 [PubMed - indexed for MEDLINE]Related articles

Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.

Plosker GL, Keam SJ.

BioDrugs. 2006;20(4):259-62. Review.PMID: 16831025 [PubMed - indexed for MEDLINE]Related articles

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL.

Clin Cancer Res. 2007 Aug 15;13(16):4909-19.PMID: 17699871 [PubMed - indexed for MEDLINE]Related articlesFree article

Her2-positive breast cancer: herceptin and beyond.

Dean-Colomb W, Esteva FJ.

Eur J Cancer. 2008 Dec;44(18):2806-12. Epub 2008 Nov 18. Review.PMID: 19022660 [PubMed - indexed for MEDLINE]Related articles